MDM2 degraders and uses thereof

A method of treating an MDM2-mediated disorder, disease, or condition in a patient, comprising administering to said patient a compound of formula I-bbb-4:

• or a pharmaceutical composition thereof, wherein:
• X1 is —C(O)—;
• R1 is hydrogen;
• each R2 is independently C1-6 aliphatic, halogen, —CN, or —OC1-6 aliphatic;
• m is 0, 1, or 2;
• Ring A is
• R4 is C1-6 aliphatic;
• Ring B is a fused ring selected from 6-membered aryl or heteroaryl containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• R1″ is selected from hydrogen and C1-6 aliphatic;
• R10 is
• R12 and R13 are taken together to form
• R18b, R18c, and R18d are each independently selected from hydrogen, halogen, C1-6 aliphatic, and —OC1-6 aliphatic;
• Q1 is a bivalent group selected from alkylenyl, phenylenyl, cycloalkylenyl, and heterocyclenyl;
• and
• L is
• wherein the compound of formula I-bbb-4 effectuates degradation of MDM2 protein in the patient, and wherein the MDM2-mediated disorder, disease, or condition is cancer.